A pilot study to evaluate efficacy and safety of sofosbuvir and daclatasvir for HCV genotype 3 infection in HIV and HCV co-infected hemophiliacs
Not Applicable
- Conditions
- HIV infection, AIDS, Chronic hepatitis C infection
- Registration Number
- JPRN-UMIN000019659
- Lead Sponsor
- ational center for global health and medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
Decompensated liver disease Severe renal impairment eGFR less than 30mL per min per 1.73m2 HBsAg seropositive Presence of active AIDS defining opportunistic infections to treat Use of prohibited treatments rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital, dexamethasone, St. John's wort containing food Any other medical, psychiatric or social reason wich, in the opinion of the investigator would make the subject inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is a sustained virologic response at week 12 after the end of therapy.
- Secondary Outcome Measures
Name Time Method